EGFR and non-small cell lung carcinoma: Focusing on these results and following the strong evidence of increased benefit from combining an EGFR-TKI with chemotherapy in treatment-naïve advanced EGFR-mutant NSCLC [52], clinical trials have been designed to evaluate this strategy in the neoadjuvant setting as well.